🔍

RPGLIFE - RPG LifeScience.

📊 NSE: RPGLIFE 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/14/2025 12:28

📢 Recent Corporate Announcements

RPG Life Sciences Clarifies Identical Q3 Results; API Division Spin-off to Subsidiary Underway

🟡 NEUTRAL ⭐ 6/10

REGULATORY 📅 09 Feb 2026, 01:11 PM

RPG Life Sciences clarified to the NSE that its standalone and consolidated financial results for Q3 FY26 are identical because its new subsidiary, RPG Active Pharma Limited, only commenced operations on January 6, 2026. The company reported a Q3 revenue of ₹18,003 Lakhs and a Profit After Tax of ₹2,213 Lakhs. Results were impacted by a one-time exceptional charge of ₹1,108 Lakhs due to the implementation of New Labour Codes. The internal reorganization to transfer the API division is expected to be completed by February 2026 to streamline business focus.

Q3 FY26 Revenue from operations stood at ₹18,003 Lakhs, a growth from ₹17,271 Lakhs in the previous year's corresponding quarter.
Net Profit for the quarter was ₹2,213 Lakhs, after accounting for a ₹1,108 Lakhs exceptional expense for New Labour Code obligations.
The company is transferring its API division to a new wholly-owned subsidiary, RPG Active Pharma Limited, incorporated on December 24, 2025.
Insurance recovery for the January 2025 fire incident is progressing, with ₹2,050 Lakhs received against a total loss of ₹2,295 Lakhs.
Nine-month FY26 Revenue reached ₹53,063 Lakhs with a Net Profit of ₹8,527 Lakhs.

💡 Investors should monitor the completion of the API division transfer and its impact on operational efficiency. The exceptional hit from the New Labour Code is a one-time regulatory adjustment and does not reflect on core business performance.

RPG Life Sciences Q3 FY26: Revenue Up 4.2% to ₹180 Cr, PAT Declines 20% YoY

🔴 NEGATIVE ⭐ 8/10

EARNINGS 📅 28 Jan 2026, 12:02 PM

RPG Life Sciences reported a modest 4.2% YoY revenue growth in Q3 FY26, reaching ₹180 crore, primarily driven by a 12.5% growth in its Domestic Formulations segment. However, profitability faced significant pressure as PAT declined 20% YoY to ₹27.9 crore and EBITDA margins contracted from 30.4% to 24.0%. The API segment was particularly weak, with a 19.4% revenue decline in 9M FY26 due to a fire incident at a manufacturing block. Despite these headwinds, the company remains debt-free and is proceeding with a ₹140 crore capex plan for global expansion.

Q3 FY26 Revenue grew 4.2% YoY to ₹180 Cr, while 9M FY26 Revenue rose 4.0% to ₹530.6 Cr.
PAT for Q3 FY26 dropped 20% YoY to ₹27.9 Cr, with EBITDA margins contracting to 24.0% from 30.4%.
Domestic Formulations, contributing 70% of sales, grew 12.5% in 9M FY26, outperforming market growth.
API segment revenue fell 19.4% in 9M FY26, impacted by a fire incident in one of the manufacturing blocks.
The company maintains a debt-free balance sheet and is investing ₹140 Cr in capex to expand its international footprint.

💡 The significant margin contraction and the fire-related disruption in the API segment are short-term negatives. Investors should watch for the recovery of API operations and the impact of the ₹140 crore capex on future growth before increasing exposure.

RPG Life Sciences Q3 FY26: Revenue up 4% to ₹180 Cr; PAT drops 20% on API Segment Fire Disruption

🔴 NEGATIVE ⭐ 7/10

EARNINGS 📅 27 Jan 2026, 08:35 PM

RPG Life Sciences reported a modest 4.2% YoY revenue growth to ₹180.0 crore for Q3 FY26, but profitability faced significant pressure. PAT declined by 19.8% to ₹27.9 crore, and EBITDA margins contracted from 30.4% to 24.0% YoY. The performance was primarily dragged down by the API segment, which saw a 19.4% revenue decline in 9M FY26 due to a fire incident at a manufacturing block. Despite this, the Domestic Formulations business grew 8.9% and the company remains debt-free with a ₹140 crore capex plan for global expansion.

Q3 FY26 Revenue grew 4.2% YoY to ₹180.0 Cr, while 9M FY26 Revenue reached ₹530.6 Cr (+4% YoY).
PAT for Q3 FY26 fell 19.8% to ₹27.9 Cr, and EBITDA declined 17.7% to ₹43.2 Cr.
API segment revenue for 9M FY26 dropped 19.4% to ₹61.7 Cr following a fire incident in a manufacturing block.
Domestic Formulations (71% of total sales) grew 8.9% in 9M FY26, reaching ₹364.6 Cr.
Company remains debt-free and is executing a ₹140 Cr capex for international market expansion.

💡 Investors should monitor the timeline for the full restoration of the API manufacturing block and the impact of the ₹140 crore capex on future growth. While the domestic business remains a strong anchor, the short-term margin compression warrants a cautious approach until API operations normalize.

RPG Life Sciences Q3 FY26 Revenue Up 4.2% Y-o-Y to Rs 180 Cr; EBITDA Margin at 24%

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 27 Jan 2026, 07:56 PM

RPG Life Sciences reported a steady performance for Q3 FY26 with revenue growing 4.2% Y-o-Y to Rs 180.0 crores. The company maintained a healthy EBITDA margin of 24.0%, reflecting operational efficiency despite a marginal Q-o-Q revenue dip from Rs 181.7 crores. Notably, the Domestic Formulations segment grew by 11.8% in the first nine months of FY26, significantly outperforming the Indian Pharmaceutical Market (IPM) growth of 8.2%. Overall 9M FY26 revenue reached Rs 530.6 crores, up from Rs 510.3 crores in the previous year.

Q3 FY26 Revenue grew 4.2% Y-o-Y to Rs 180.0 crores vs Rs 172.7 crores in Q3 FY25
EBITDA margin remained robust at 24.0% for the quarter
Domestic Formulations business grew 11.8% in 9M FY26, outperforming the IPM growth of 8.2%
9M FY26 total revenue reached Rs 530.6 crores, a 4.0% increase Y-o-Y
Q-o-Q revenue saw a slight decline from Rs 181.7 crores to Rs 180.0 crores

💡 Investors should take note of the company's consistent ability to outperform the domestic pharma market growth and maintain high margins. The stock remains a solid mid-cap pharma play focused on branded formulations and operational efficiency.

RPG Life Sciences Approves Q3 FY26 Unaudited Financial Results

🟡 NEUTRAL ⭐ 7/10

EARNINGS 📅 27 Jan 2026, 07:47 PM

RPG Life Sciences Limited has officially approved its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The board meeting, held on January 27, 2026, concluded with the submission of these results along with the Statutory Auditor's Limited Review Report. While the specific profit and revenue figures were not detailed in the cover letter, the filing confirms compliance with SEBI Listing Obligations. Investors should now examine the full financial tables to evaluate the company's performance trajectory for the fiscal year.

Board approved unaudited financial results for the quarter ended December 31, 2025
Consolidated and standalone results for the nine-month period were submitted to exchanges
The board meeting lasted three and a half hours, concluding at 6:30 p.m.
Statutory auditors have provided a Limited Review Report for the period

💡 Investors should review the detailed profit and loss statements to assess margin trends and revenue growth compared to the previous year. Monitor the stock's price action in the coming sessions for the market's reaction to the specific earnings data.

RPG Life Sciences Board Approves Q3 FY26 Unaudited Financial Results

🟡 NEUTRAL ⭐ 7/10

EARNINGS 📅 27 Jan 2026, 07:33 PM

RPG Life Sciences Limited held its board meeting on January 27, 2026, to approve the unaudited financial results for the quarter and nine months ended December 31, 2025. The board reviewed both standalone and consolidated financial statements, ensuring compliance with SEBI Listing Obligations. The meeting, which lasted three and a half hours, concluded with the submission of the results and the statutory auditor's Limited Review Report. This is a routine but critical regulatory update for the third quarter of the 2025-26 fiscal year.

Board approved unaudited standalone and consolidated financial results for Q3 FY26.
Financial results cover the nine-month period ending December 31, 2025.
Statutory Auditors issued a Limited Review Report on the financial statements.
The board meeting was conducted from 03:00 p.m. to 06:30 p.m. on January 27, 2026.

💡 Investors should examine the detailed financial tables and auditor's report once released to evaluate the company's revenue growth and margin stability. Compare the Q3 performance against year-on-year benchmarks to assess long-term value.

RPG Life Sciences Submits SEBI Compliance Certificate for Q3 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 09 Jan 2026, 06:42 PM

RPG Life Sciences Limited has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by MUFG Intime India Private Limited, confirms that all share dematerialization requests received during the quarter ended December 31, 2025, were processed within prescribed timelines. The registrar confirmed that physical certificates were mutilated and cancelled after verification. This is a standard regulatory filing ensuring the integrity of the company's shareholding records.

Compliance certificate issued for the quarter ended December 31, 2025
Confirmation provided by Registrar and Transfer Agent, MUFG Intime India Private Limited
Securities received for dematerialization were processed and listed on stock exchanges
Physical certificates were mutilated and cancelled as per SEBI guidelines within timelines

💡 No action is required as this is a routine administrative filing. Investors should monitor the company's upcoming quarterly financial results for material performance updates.

RPG Life Sciences Receives GST Demand Order of ₹1.08 Crore

🟡 NEUTRAL ⭐ 3/10

LEGAL 📅 29 Dec 2025, 04:47 PM

RPG Life Sciences has received a tax demand order from the State Tax Officer, Maharashtra, for the period April 2021 to March 2022. The total demand amounts to ₹1.08 crore, which includes tax, interest, and penalty components. The company has stated its intention to contest the order through appropriate legal channels. Management currently does not foresee any material financial impact on the company's operations from this development.

Total demand of ₹1,07,81,869 issued under Section 73 of the GST Act, 2017.
The demand consists of ₹52,85,230 in tax, ₹44,39,593 in interest, and ₹10,57,046 in penalty.
The order pertains to the tax period from April 2021 to March 2022.
Company is pursuing legal remedies to contest the demand and expects no material financial impact.

💡 Investors should treat this as a routine regulatory matter as the demand amount is not significant relative to the company's scale. No immediate portfolio action is required.

RPG Life Sciences Incorporates Wholly Owned Subsidiary RPG Active Pharma Limited

🟢 POSITIVE ⭐ 6/10

EXPANSION 📅 24 Dec 2025, 10:11 PM

RPG Life Sciences Limited has officially incorporated a new wholly owned subsidiary named RPG Active Pharma Limited on December 24, 2025. This move follows the company's prior intimation on December 15, 2025, regarding the strategic intent to form this entity. The new subsidiary is registered under CIN U21001MH2025PLC464091 and is expected to focus on specialized pharmaceutical operations. This structural expansion indicates a potential focus on the Active Pharmaceutical Ingredients (API) segment or a dedicated business vertical to drive future growth.

Incorporated a 100% wholly owned subsidiary named RPG Active Pharma Limited on December 24, 2025
The new entity is registered under Corporate Identification Number (CIN) U21001MH2025PLC464091
The incorporation follows a prior regulatory intimation dated December 15, 2025
The move aligns with the company's long-term growth strategy within the pharmaceutical sector

💡 Investors should monitor future announcements regarding the specific business objectives and capital expenditure plans for this new subsidiary. This expansion could potentially enhance the company's manufacturing capabilities and market reach in the API segment.

RPG Life Sciences to Close Trading Window from Jan 1, 2026 for Q3 FY26 Results

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 24 Dec 2025, 05:08 PM

RPG Life Sciences Limited has announced the closure of its trading window for designated persons starting January 1, 2026. This action is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the company's Q3 and nine-month financial results for the period ending December 31, 2025. The window will remain closed until 48 hours after the financial results are officially declared. The specific date for the board meeting to approve these results is yet to be announced.

Trading window closure commences on January 1, 2026.
Closure pertains to the unaudited financial results for the quarter and nine months ending December 31, 2025.
Restriction applies to all designated persons and their immediate relatives.
The window will reopen 48 hours after the results are disclosed to the stock exchanges.

💡 This is a standard regulatory procedure and does not impact the company's fundamentals. Investors should monitor for the upcoming board meeting date announcement to track the Q3 earnings performance.

RPGLIFE: Key Managerial Personnel Authorized as of December 15, 2025

🟡 NEUTRAL ⭐ 5/10

MANAGEMENT 📅 15 Dec 2025, 03:41 PM

RPG Life Sciences has authorized key managerial personnel (KMP) for determining the materiality of events and for making disclosures to stock exchanges, effective December 15, 2025. Mr. Ashok Nair (Managing Director) and Mr. Amol Lone (Chief Financial Officer) are jointly authorized to determine materiality. For disclosures, Mr. Rajesh Shirambekar (Head- Legal & Company Secretary) is also authorized severally. Investors should note these changes in authorized personnel for company communications.

Mr. Ashok Nair is the Managing Director authorized for materiality determination.
Mr. Amol Lone is the Chief Financial Officer authorized for materiality determination.
Mr. Rajesh Shirambekar is the Head- Legal & Company Secretary authorized for disclosures.
Authorization effective from December 15, 2025.

💡 Investors should take note of the authorized personnel for future communications and disclosures from the company. Monitor company announcements for any material events as determined by the authorized KMPs.

RPG Life Sciences Authorizes KMPs for Materiality Determination and Disclosures

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 15 Dec 2025, 03:36 PM

RPG Life Sciences has updated its list of authorized Key Managerial Personnel (KMP) for determining the materiality of information and making disclosures to stock exchanges. Effective December 15, 2025, the Managing Director and CFO are jointly responsible for determining materiality. For the actual filing of disclosures, the MD, CFO, and Company Secretary are severally authorized. This update ensures compliance with Regulation 30(5) of SEBI (LODR) Regulations, 2015.

Board authorized KMPs for materiality determination effective December 15, 2025
Managing Director Ashok Nair and CFO Amol Lone are jointly authorized to determine materiality
MD, CFO, and Company Secretary Rajesh Shirambekar are severally authorized for stock exchange disclosures
The update is in compliance with Regulation 30(5) of SEBI (LODR) Regulations, 2015

💡 This is a routine administrative update regarding corporate governance and compliance. No immediate action is required from investors as it does not affect the company's business fundamentals.

RPGLIFE appoints Amol Lone as CFO, to incorporate RPG Active Pharma

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 15 Dec 2025, 03:31 PM

RPG Life Sciences has appointed Mr. Amol Lone as the Chief Financial Officer (CFO) effective December 15, 2025. The company will also incorporate a wholly-owned subsidiary, "RPG Active Pharma Limited," for manufacturing and marketing active pharmaceutical ingredients (API). RPGLIFE plans to transfer its existing API business, which contributed ₹90.24 crores (13.8%) to FY25 turnover, to the new subsidiary. An investment of up to ₹105 crore will be made in the WOS in one or more tranches.

Amol Lone appointed as CFO effective December 15, 2025
API business contributed ₹90.24 crores to FY25 turnover
API business net worth as on March 31, 2025 was ₹90.61 crores
Investment of up to ₹105 crore in the new WOS
Consideration for API business transfer expected to be approximately ₹50 crore

💡 Investors should monitor the progress of the API business transfer and the performance of the new subsidiary, RPG Active Pharma Limited. Keep an eye on how the ₹105 crore investment impacts the company's growth and profitability.

RPGLIFE Board approves API business transfer to new wholly-owned subsidiary

🟡 NEUTRAL ⭐ 6/10

BOARD_MEETING 📅 15 Dec 2025, 03:27 PM

RPG Life Sciences' board approved the transfer of its API business, which contributed ₹90.24 crore (13.8%) to FY25 turnover, to a new wholly-owned subsidiary (WOS). The net worth of the API business as of March 31, 2025, was ₹90.61 crore, representing 17.1% of the company's total net worth. The company will invest up to ₹105 crore in the WOS in tranches. The consideration for the transfer is expected to be approximately ₹50 crore.

API business contributed ₹90.24 crore to FY25 turnover (13.8%).
Net worth of API business was ₹90.61 crore as of March 31, 2025 (17.1% of total).
Investment of up to ₹105 crore in the WOS.
Consideration for API business transfer expected to be approximately ₹50 crore.

💡 Investors should monitor the progress of the API business transfer and the performance of the new subsidiary. Keep an eye on how the ₹105 crore investment impacts the company's growth.

View All RPGLIFE Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Domestic Formulations grew 10.1% YoY to INR 425.00 Cr in FY25. Overall revenue showed a 5-year CAGR of ~12% ending FY24, with 13% growth in FY24 and 12% in 9M FY25. Q2 FY26 revenue reached INR 181.7 Cr, a 7.6% increase over Q1 FY26.

Geographic Revenue Split

Domestic Formulations is the primary driver, contributing ~67% of total revenue in FY24. The remaining 33% is derived from International Formulations and API segments across regulated markets like the EU, Australia, and Japan.

Profitability Margins

Operating Profit Margin (OPM) improved from 19.8% in FY22 to 20.4% in FY23, 22.2% in FY24, and reached 26.3% in 9M FY25. PAT margin stood at 15.6% in Q2 FY26 (INR 28.5 Cr).

EBITDA Margin

EBITDA margin was 24.0% in Q2 FY26 (INR 43.6 Cr), up from 21.0% in Q1 FY26. The 5-year OPBIDTA CAGR is ~29%, reflecting significant operational scaling and cost optimization.

Capital Expenditure

The company has no major debt-funded capex plans. Recent investments focused on modernizing manufacturing plants and capacity enhancements. Liquidity was bolstered by monetizing surplus land at the API plant in February 2025.

Credit Rating & Borrowing

Long-term rating upgraded to [ICRA]A+ (Stable) in March 2024 from [ICRA]A (Stable). Short-term rating reaffirmed at [ICRA]A1. The company is virtually debt-free with a Total Debt/OPBDITA of 0.004x as of September 2022.

⚙️ Operational Drivers

Raw Materials

Bulk drugs and intermediates for API and formulation manufacturing. Specific names not listed, but they include inputs for immunosuppressants and anti-diarrheals.

Import Sources

Significant portion of raw materials and intermediates are dependent on imports, particularly for the API segment, making margins sensitive to global price volatility.

Key Suppliers

Not specifically named in documents; however, the company monitors concentration of purchases with trading houses and related parties.

Capacity Expansion

Capacity enhancements are ongoing to support a 12% revenue CAGR. The company has modernized both manufacturing plants to secure international regulatory approvals.

Raw Material Costs

Margins are susceptible to raw material price fluctuations. Procurement strategies focus on cost rationalization and optimizing the product mix toward higher-margin international formulations.

Manufacturing Efficiency

Efficiency is driven by cost rationalization and a shift toward high-margin specialty products. Operating margins reached a peak of 26.3% in 9M FY25 due to these measures.

Logistics & Distribution

The company is expanding its field force and deploying digital solutions to enhance sales force effectiveness and distribution reach in targeted therapies.

📈 Strategic Growth

Expected Growth Rate

12%

Growth Strategy

Growth is targeted through five pillars: Product Portfolio Rejuvenation (building chronic/specialty portfolios), Strategic Brand Asset Building (life cycle management), Customer Coverage Deepening (expanding field force), Sales Force Effectiveness, and Profitability Improvement (optimizing manufacturing).

Products & Services

Pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs) for Nephrology (immunosuppressants), Gastro-intestinal (anti-diarrheal), Pain Management, Cardiovascular, Oncology, and Rheumatology.

Brand Portfolio

Not specifically listed by name, but the company relies on a few 'top brands' in the domestic market which drive the majority of revenue.

New Products/Services

Launched 12 new products in FY24 and 17 in 9M FY25. Sales from new products launched since FY19 now contribute ~25% of total domestic formulation sales.

Market Expansion

Focusing on increasing presence in existing geographies and exploring new markets after re-evaluating and deferring US market entry.

Market Share & Ranking

Holds strong market share in niche therapeutic segments like Nephrology (immunosuppressants) and Gastro-intestinal (anti-diarrheal).

Strategic Alliances

Exited biotech API segment via a slump sale to Intas Pharmaceuticals Limited in 2016 for INR 25.0 Cr to focus on core formulations.

🌍 External Factors

Industry Trends

The industry is shifting toward chronic and specialty therapies. RPGLS is positioning itself by rejuvenating its portfolio in these high-growth areas and maintaining global manufacturing compliance.

Competitive Landscape

Operates as a mid-sized player facing competition from both large Indian pharma companies and multinational corporations in regulated markets.

Competitive Moat

Moat is built on strong brand equity in specialized therapies (Nephrology) and a debt-free balance sheet providing high financial flexibility. Sustainability is supported by the RPG Group lineage.

Macro Economic Sensitivity

Sensitive to economic developments in India and changes in demand/supply conditions within the global pharmaceutical industry.

Consumer Behavior

Increasing demand for chronic disease management and specialty medicines is driving the company's shift toward these portfolios.

Geopolitical Risks

Trade barriers or regulatory changes in export markets (EU, Australia, Japan) could impact the international formulations business.

⚖️ Regulatory & Governance

Industry Regulations

Strict adherence to EU GMP, WHO GMP, TGA Australia, PMDA Japan, and NDPS certifications. Susceptible to social risks related to product safety and government price controls.

Taxation Policy Impact

Subject to Indian corporate tax laws and international tax regulations for export revenue.

Legal Contingencies

No fines or penalties related to corruption or conflict of interest were reported for FY25. Secretarial audit is conducted to ensure compliance with statutory records.

⚠️ Risk Analysis

Key Uncertainties

Adverse regulatory observations from health authorities could impact manufacturing and profitability. Sustained deterioration in RoCE below 16% is a key rating monitorable.

Geographic Concentration Risk

67% of revenue is concentrated in the Indian domestic market, making it sensitive to local regulatory and economic shifts.

Third Party Dependencies

Dependency on external suppliers for imported raw materials and intermediates poses a risk to margin stability.

Technology Obsolescence Risk

The company is mitigating technology risks by modernizing plants and deploying digital solutions for sales force effectiveness.

Credit & Counterparty Risk

Receivables quality is supported by a stable working capital cycle and strong liquidity, with cash and liquid investments of INR 126 Cr as of Sept 2024.